Richards, Erica M.
Mathews, Daniel C.
Luckenbaugh, David A.
Ionescu, Dawn F.
Machado-Vieira, Rodrigo
Niciu, Mark J.
Duncan, Wallace C.
Nolan, Neal M.
Franco-Chaves, Jose A.
Hudzik, Thomas
Maciag, Carla
Li, Shuang
Cross, Alan
Smith, Mark A.
Zarate, Carlos A. Jr.
Funding for this research was provided by:
National Institute of Mental Health (08-M-0196)
Brain and Behavior Research Foundation
NARSAD
Article History
Received: 18 August 2015
Accepted: 14 December 2015
First Online: 4 January 2016
Compliance with ethical standards
: The study was approved by the Combined Neuroscience Institutional Review Board (IRB) at the NIH. All subjects provided written informed consent before entry into the study and were assigned a Clinical Research Advocate from the NIMH Human Subjects Protection Unit to monitor the consent process and research participation throughout the study.
: The authors declare that they have no competing interests.
: Funding for this work was supported in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; NCT00759395, protocol 08-M-0196), by a NARSAD Independent Investigator to Dr. Zarate, and by a Brain & Behavior Mood Disorders Research Award to Dr. Zarate. These funding sources had no further role in study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. A patent for the use of ketamine in depression has been awarded that lists Dr. Zarate among the inventors; he has assigned his rights on the patent to the US government, but will share a percentage of any royalties that may be received by the government. Carla Maciag and Drs. Mark Smith, Thomas Hudzik, and Alan Cross were full-time employees of AstraZeneca Neuroscience Innovative Medicines at the time the study was conducted. AstraZeneca Pharmaceuticals provided the study compound.